Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACT#001 CAR-T Cells in Castration-Resistant Prostate Cancer
NCT07240857Phase 1Enrolling by invitation
- Sponsor
- Zhejiang University
- Start
- Apr 2026
- Primary completion
- Oct 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of ACT#001-PSMA CAR-T in castration-resistant prostate cancer (CRPC) (2 arms), sponsored by Zhejiang University. Primary endpoint: Dose-Limiting Toxicity at 28 days. Started Apr 2026; status: enrolling by invitation.
02
Drugs
ACT#001-PSMA CAR-T
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT07240857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07240857.